Alpha Capital
VC Fund
Chicago, United States
Alpha Capital is a VC fund in Chicago focused on Biotechnology and Health Care. Founded in 1984, Alpha Capital is a private equity investment firm which provides equity financing for promising growth businesses and for buyouts or recapitalizations of established companies. The investment activity of Alpha Capital is concentrated in the greater Midwest, however, Alpha will consider investments on nationwide basis.Currently,Alpha Capital Partners and affiliates manage over $135,000,000 in three venture capital partnerships and other equity accounts. With approximately $90 million of capital, Alpha Capital's latest limited partnership fund is actively investing at this time.A subsidiary of the most recent fund is federally licensed as a Small Business Investment Company (SBIC).
- Total investments:
- 25
- Last investment:
- Lead investor:
- 32%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Alpha Capital invests in
Stages Alpha Capital invests in
Countries Alpha Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $15M–$58M
- Venture - Series Unknown
- $3.2M–$22M
Investment Focus
Industry
- Biotechnology 5 (20%)
- Health Care 4 (16%)
- Information Technology 4 (16%)
- Artificial Intelligence 4 (16%)
- Software 3 (12%)
Stage
- Funding Round 6 (24%)
- Venture - Series Unknown 6 (24%)
- Series A 4 (16%)
- Post-IPO Equity 4 (16%)
- Seed 2 (8%)
Country
- United States 11 (44%)
- India 6 (24%)
- Israel 2 (8%)
- France 1 (4%)
- Vietnam 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew H. Kalnow
President
|
President | Total investments: 0 | Find email | |
J. Dirk Vos
Chairman
|
Chairman | Total investments: 0 | Find email | |
Jean Sommer
Controller and Corporate Officer
|
Controller and Corporate Officer | Total investments: 0 | Find email | |
|
John W. Rose
Principal
|
Principal | Total investments: 0 | Find email | |
Murtaza Hussain
Analyst
|
Analyst | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Sportix.ai
|
Sportix.ai is a sports AI-powered intelligent infrastructure platform. | $3.2M / Venture - Series Unknown / May 08, 2026 | |
DeepBook AI
|
Deepbook is a developer of an AI-powered decentralized web browsing platform enabling secure, censorship-resistant access to Web3 resources. | $2M / Seed / Dec 19, 2025 | |
VIXO
|
VIXO Protocol (vixo.vip) is a decentralized, collateral-backed stablecoin protocol primarily collateralized by major assets like BTC, ETH, and BNB, designed to enable self-custodied minting, optional privacy via zero-knowledge proofs, verifiable stability mechanisms, and unfreezeable assets for censorship-resistant finance. | Venture - Series Unknown / Dec 02, 2025 | |
Raiinmaker
|
Raiinmaker offers a social engagement platform, allowing the community and project to collaborate for mutual gain. The platform collects data on social engagements using distributed ledger technology to capture, measure, and distribute the value of collective social interactions. All of a user's interactions and referrals are combined to givea comprehensive view, allowing projects to better assess returns on digital interactions and reward influencers and affiliates alike. Align incentives with brand objectives to increase word-of-mouth and fan affinity. Fans should be able to explore, progress, and receive rewards through social activity. | $7.5M / Seed / Apr 03, 2024 | |
Kuros Biosciences
|
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed fromwork carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology.Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU.Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications. | $6.2M / Post-IPO Equity / Sep 15, 2022 | |
Diagnostic Robotics
|
Diagnostic Robotic develops a signal-agnostic artificial intelligence system for healthcare insurers, providers, and patients. It allows building powerful predictive analytics models that will solve a world-wide challenge, strained health budgets, and workforces. Diagnostic Robotic was founded on 2017 and is headquartered in Tel Aviv, Israel. | $45M / Series B / Jul 25, 2022 | |
Nanofabrica
|
Nanofabrica brings the power of 3D printing to micro and nanomanufacturing. Their patent-pending technology opens new markets for 3D printing such as robotics, bio-medical, semiconductors. Enabling mass customization of precise and complex parts at competitive prices. Most of our technology is developed through direct feedback from customers, sowe are always interested in new and challenging projects. Their industrial Additive Manufacturing systems have an unprecedented micron-resolution with ultra-high features, details, accuracy, and precision– enabled by the innovative Micro Adaptive Projection technology. | $4M / Venture - Series Unknown / May 10, 2020 | |
|
Diagnostic Robotics
|
Diagnostic Robotic develops a signal-agnostic artificial intelligence system for healthcare insurers, providers, and patients. It allows building powerful predictive analytics models that will solve a world-wide challenge, strained health budgets, and workforces. Diagnostic Robotic was founded on 2017 and is headquartered in Tel Aviv, Israel. | $24M / Series A / Nov 13, 2019 | |
Shree
|
Shree is based on the idea that you should never go out of vogue. Providing fast-fashion Indian wear along with unmatched value for the new age women, Shree has swiftly become one of the top seller brands on all the leading ecommerce stores like Snapdeal, Myntra, Jabong, Flipkart, Fashion and You, eBay, Homeshop18, Limeroad, India Emporium andmore. We have 25 + exclusive Brand outlets in Delhi NCR, Telangana, Surat, Hissar and Uttarkhand. Our strong network of dealers and distributors, wholesalers and retailers, MBO’s in various states facilitate Shree to showcase products in 2000+ stores. | $11.5M / May 08, 2019 | |
SHREE
|
SHREE is an Indian ethnic wear brand offering women's clothing, including kurtas, salwar kameez sets, ethnic sets, and tunics. The brand began as an e-commerce platform and has expanded to over 100 retail outlets both domestically and internationally. SHREE emphasizes comfort and everyday wearability in its designs, catering to diverse bodytypes and climates. The brand's design philosophy combines traditional elements with contemporary styles to meet the modern Indian woman's needs. | $11.5M / Venture - Series Unknown / May 08, 2019 | |
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alpha Capital invest in?
Alpha Capital invests primarily in Biotechnology, Health Care and Information Technology startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alpha Capital's check size?
Alpha Capital typically joins rounds of $15M–$58M at Series A and $3.2M–$22M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alpha Capital participates in.
How do I contact Alpha Capital?
Public channels for Alpha Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alpha Capital?
The team at Alpha Capital includes Andrew H. Kalnow (President), J. Dirk Vos (Chairman) and Jean Sommer (Controller and Corporate Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
